Business Context and Reporting Period
Company: IMMUCELL CORP
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2002
Business Overview: The Company operates in two primary segments: Animal Health Products and Research & Development (R&D). Its principal customers are in the U.S. and foreign dairy and beef industries. Key products include FIRST DEFENSE(R) and the KAMAR(R) HEATMOUNT(R) DETECTOR.
Key Financial Metrics
| Metric | Q1 2002 | Q1 2001 |
|---|---|---|
| Total Revenues | $1,896,674 | $1,488,678 |
| Product Sales | $1,778,657 | $1,470,278 |
| Gross Margin (Product Sales) | 52% | 53% |
| Net Income | $169,055 | $116,107 |
| EPS (Diluted) | $0.06 | $0.04 |
| Net Cash from Operating Activities | $288,360 | $188,735 |
| Cash and Cash Equivalents (End of Period) | $1,969,143 | $1,918,841 |
| Total Debt (Current + Long-Term) | $408,659 | $414,178 |
| Working Capital | $3,310,063 | $2,943,000 (Dec 31, 2001) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 27% ($408,000) year-over-year. Product sales rose 21% ($308,000), driven by a 24% increase in combined sales of FIRST DEFENSE and KAMAR HEATMOUNT DETECTOR. The prior year's Q1 was constrained by a $1,000,000 order backlog which was resolved by December 2001 following a facility expansion.
- Profitability: Net income increased 46% ($53,000) to $169,055. Income before taxes rose 49% to $287,000.
- Expense Trends:
- R&D expenses increased 21% to $200,000, primarily due to the development of the MAST OUT(TM) product.
- Sales and marketing expenses increased 22% to $391,000.
- General and administrative expenses increased 18% to $156,000.
- Liquidity: Cash and short-term investments increased by approximately $281,000 to $2,164,000. Net working capital improved by $367,000.
Outlook, Risks, and Management Commentary
- Debt Repayment: In May 2002 (post-period), the Company utilized approximately $405,000 in cash to fully repay its outstanding bank mortgage. The Company currently has no outstanding bank debt.
- R&D Focus: Management anticipates increased R&D expenses later in the year as the MAST OUT(TM) product advances to clinical trials. The Company targets investing 10% to 13% of product sales in R&D, though MAST OUT development costs are higher than typical animal health products.
- Deferred Revenue: As of March 31, 2002, $251,000 was recorded as deferred revenue, including $150,000 from a State of Maine grant (contingent payback) and licensing fees recognized over time.
- Liquidity Outlook: Management believes capital resources are sufficient to meet working capital requirements for at least the next twelve months.
- Risks: Forward-looking statements are subject to risks regarding regulatory approval (FDA), product development delays, and market competition. One-time expenditures for MAST OUT could temporarily impact quarterly profitability targets.
Key Facts for Investor Verification
- Debt Status: Verify the full repayment of the $408,659 mortgage balance in May 2002 as stated in the notes.
- Grant Contingencies: Review the terms of the $150,000 State of Maine grant recorded as deferred revenue due to contingent payback obligations.
- R&D Spend Trajectory: Monitor upcoming quarters for the anticipated spike in R&D expenses related to MAST OUT(TM) clinical trials.
- Revenue Concentration: Note that 75% of product sales come from the U.S. dairy and beef industry, with 25% from foreign customers.
- Product Mix: Confirm that FIRST DEFENSE and KAMAR HEATMOUNT DETECTOR continue to represent approximately 91% of total product sales.